

INDEPENDENT AUDITORS' REPORT

To the Members of Dialforhealth Unity Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **Dialforhealth Unity Limited** ('the Company'), which comprise the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss (including other comprehensive income), the Statement of cash flows and the Statement of changes in Equity for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ('Ind AS') and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its loss, total comprehensive income, cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Information other than the Financial Statements and Auditor's Report thereon

- The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Directors' Report, but does not include the financial statements and our audit reports thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for

safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our

audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept, so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement and Statement of Changes in Equity dealt with by this report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, no remuneration has been paid by the Company to its directors during the year.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations given under (a) and (b) above, contain any material misstatement.
- v. No dividend is declared or paid during the year by the company, so reporting under clause 11(f) of Rule 11 of the Companies (Audit and Auditors) Rules, 2014, is not applicable.
- vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended 31st March, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instances of the audit trail feature being tempered with. The audit trail has been preserved by the company as per the statutory requirements for record retention.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

Place: Ahmedabad
Date: 30th April, 2026
UDIN: 26042132OPESHO4017

sd/-
Chandresh S. Shah
Partner
Membership No.: 042132

“Annexure A” to the Independent Auditors’ Report

The Annexure referred to in Independent Auditors’ Report to the members of the Company on the financial statements for the year ended March 31, 2026.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

1. The company does not hold any Property, Plant and Equipment or Intangible Assets, hence clause (i) (a), (i)(b), (i)(c), (i)(d) and (i) (e) of Paragraph 3 of the Order are not applicable to the company for the year under review.
2. The company does not deal in inventory hence this clause is not applicable to the company for the year under review.
3. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments in, provided any guarantee or security, and granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year, and hence reporting under clause (iii) of the Order is not applicable.
4. According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security or made any investments to which provisions of Section 185 and Section 186 of the Companies Act, 2013 are applicable, and accordingly paragraph 3(iv) of the Order is not applicable to the company.
5. The Company has not accepted any deposits within the meaning of the provisions of section 73 to 76 of the Act or any other relevant provisions of the Act and the rules framed thereunder. Further, according to the information and explanations given to us, no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other Tribunal, in this regard.
6. In absence of any manufacturing activity carried out by the company, the requirement of maintenance of cost records under sub section 1 of section 148 of the Companies Act, 2013 are not applicable to the company.
7. (a) According to the information and explanations given to us and on the basis of our examination of the records, the company has been regular in depositing undisputed statutory dues including Goods and Services tax, Provident Fund, Employees’ State Insurance, Income tax, Sales tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess and any other material statutory dues wherever payable have been paid during the year with the appropriate authorities. Moreover, as at 31st March 2026, there are no such undisputed dues payable for a period of more the six months from the day they became payable.

(b) According to the information and explanations given to us, there is no due under dispute for the Income Tax, Sales Tax, Value added Tax, Excise Duty and Service Tax, GST and other material statutory dues as at 31st March, 2026.
8. According to the information and explanations given to us, there were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
9. (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest to any lender during the year.

- (b) According to the information and explanations given to us and on the basis of our audit procedure, we report that the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
 - (c) According to the information and explanations given to us, the Company has not availed term loans, hence reporting under Paragraph 3(ix)(c) is not applicable.
 - (d) According to the information and explanations given to us, and the procedures performed by us, and on overall examination of financial statements of the Company, we report that funds raised on short term basis have, not been used during the year for the long-term purpose by the Company.
 - (e) According to the information and explanations given to us, and the procedures performed by us, and on overall examination of financial statements of the Company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
 - (f) According to the information and explanations given to us, and the procedures performed by us, we report that the Company has not raised any loans during the year on the pledge of securities held in its subsidiary companies.
10. (a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under this clause of the Order is not applicable to the Company.
 - (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) and hence reporting under this clause of the Order is not applicable to the Company;
 11. (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
 - (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - (c) According to the information and explanations given by management/Audit Committee, there were no whistle blower complaints received by the Company during the year.
 12. The Company is not a Nidhi Company and hence reporting under this clause of the Order is not applicable.
 13. According to the information and explanations given to us and based on our examination of the records of the Company, the Company is in compliance with section 177 and 188 of the Companies Act, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
 14. According to the information and explanations given to us and based on our examination of the records of the Company, the company is not required to undergo internal audit and hence the clause is not applicable to the company.
 15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with any of its directors or persons connected with such directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
 16. According to the information and explanations given to us and based on our examination of the records of the Company, we report that

- (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934;
 - (b) The company has not conducted any non-banking or housing finance activities during the year;
 - (c) The Company is not a Core Investment Company, as defined in the regulations made by the Reserve Bank of India;
 - (d) The Group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016) does not have more than one Core Investment Company.
17. The Company has incurred cash losses of Rs. 246 thousand in the current financial year and Rs. 201 thousand in the immediately preceding financial year.
18. There has been no resignation of the statutory auditors of the Company during the year. Accordingly, reporting under clause 3(xviii) of the Order is not applicable.
19. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
20. On the basis of information and explanations given to us and based on the examination of the records of the company, the provisions of Corporate Social Responsibility ("CSR") of the Act are not applicable to the company. Accordingly, reporting under clause 3(XX) of the Order is not applicable for the year.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

Place: Ahmedabad
Date: 30th April, 2026
UDIN: 26042132OPESHO4017

sd/-
Chandresh S. Shah
Partner
Membership No.: 042132

“ANNEXURE B” TO THE AUDITORS’ REPORT

Report on the Internal Financial Control clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **Dialforhealth Unity Limited** (“the Company”) as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial control based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India [“ICAI”]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (“the Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company’s internal financial control over financial reporting includes those policies and procedures that:

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and

- expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MUKESH M. SHAH & CO.,**
Chartered Accountants
Firm Registration No.: 106625W

Place: Ahmedabad
Date: 30th April, 2026
UDIN: 26042132OPESHO4017

sd/-
Chandresh S. Shah
Partner
Membership No.: 042132

Dialforhealth Unity Limited [CIN : U51390GJ2005PLC046314]
Balance Sheet as at March 31, 2026

Particulars	Note No.	INR-Thousands	
		As at March 31	
		2026	2025
ASSETS:			
Non-Current Assets:			
Property, Plant and Equipment	3	-	-
Financial Assets:			
Other Financial Assets	4	25	25
Current Assets:			
Financial Assets:			
Cash and Cash Equivalents	5	92	29
Total Assets		117	54
EQUITY AND LIABILITIES:			
Equity:			
Equity Share Capital	6	500	500
Other Equity	7	(3,751)	(3,505)
Total equity		(3,251)	(3,005)
Liabilities:			
Non-Current Liabilities:			
Financial Liabilities:			
Borrowings	8	2,779	2,156
Other Financial Liabilities	9	182	498
Total Non-Current Liabilities		2,961	2,654
Current Liabilities:			
Financial Liabilities:			
Trade Payables			
Dues to Micro and Small Enterprise	10	6	12
Dues to other than Micro and Small Enterprise	10	375	375
Other Financial Liabilities	11	6	-
Other Current Liabilities	12	20	18
Total Current Liabilities		407	405
Total Liabilities		3,368	3,059
Total Equity and Liabilities		117	54
Material Accounting Policies	2		
Notes to the Financial Statements	3 to 24		
As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W		For and on behalf of the Board sd/- Harish B. Sadana Director [DIN : 00026483]	
sd/- Chandresh S. Shah Partner Membership Number: 042132 Ahmedabad, Dated: April 30, 2026		sd/- Jyotindra B. Gor Director [DIN : 06439935] Ahmedabad, Dated: April 30, 2026	

Dialforhealth Unity Limited [CIN : U51390GJ2005PLC046314]
Statement of Profit and Loss for the year ended March 31, 2026

Particulars	Note No.	INR-Thousands	
		Year ended March 31	
		2026	2025
EXPENSES:			
Finance Costs	13	230	176
Other Expenses	14	16	25
Total Expenses		246	201
Loss before Tax		(246)	(201)
Less: Tax Expense	15	-	-
Loss for the year		(246)	(201)
Other Comprehensive Income for the year [Net of Tax]		-	-
Total Comprehensive Income for the year [Net of Tax]		(246)	(201)
Basic & Diluted Earnings per Equity Share [EPS] [in Rupees]	16	(4.92)	(4.02)
Material Accounting Policies	2		
Notes to the Financial Statements	3 to 24		
<u>As per our report of even date</u> For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W		<u>For and on behalf of the Board</u> sd/- Harish B. Sadana Director [DIN : 00026483]	
sd/- Chandresh S. Shah Partner Membership Number: 042132 Ahmedabad, Dated: April 30, 2026		sd/- Jyotindra B. Gor Director [DIN : 06439935] Ahmedabad, Dated: April 30, 2026	

Dialforhealth Unity Limited [CIN : U51390GJ2005PLC046314]
Statement of Changes in Equity for the year ended March 31, 2026

a Equity Share Capital:		
	No. of Shares	INR-Thousands
Equity Shares of INR 10/- each, Issued, Subscribed and Fully Paid-up:		
As at March 31, 2024	50,000	500
As at March 31, 2025	50,000	500
As at March 31, 2026	50,000	500
b Other Equity:		
	INR-Thousands	
	Reserves and Surplus	Total
	Retained Earnings	
As at March 31, 2024	(3,304)	(3,304)
Add: Loss for the year	(201)	(201)
Add: Other Comprehensive Income	-	-
As at March 31, 2025	(3,505)	(3,505)
Add: Loss for the year	(246)	(246)
Add: Other Comprehensive Income	-	-
As at March 31, 2026	(3,751)	(3,751)
<u>As per our report of even date</u> For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W <u>For and on behalf of the Board</u> sd/- Harish B. Sadana Director [DIN : 00026483] sd/- Chandresh S. Shah Partner Membership Number: 042132 Ahmedabad, Dated: April 30, 2026 sd/- Jyotindra B. Gor Director [DIN : 06439935] Ahmedabad, Dated: April 30, 2026		

Dialforhealth Unity Limited [CIN : U51390GJ2005PLC046314]

Cash Flow Statement for the year ended March 31, 2026

Particulars	INR-Thousands	
	Year ended March 31	
	2026	2025
A Cash flows from operating activities:		
Loss before tax	(246)	(201)
Adjustments for:		
Interest Expense	230	176
Operating [loss] before working capital changes	(16)	(25)
Adjustments for:		
Increase in other liabilities	8	7
[Decrease] in trade payable	(6)	-
Total	2	7
Net cash [used in] operating activities	(14)	(18)
B Cash flows from investing activities:	-	-
C Cash flows from financing activities:		
Proceeds from non current borrowings	100	-
Interest Paid	(23)	(18)
Net cash generated from/ [used in] financing activities	77	(18)
Net Increase/ [Decrease] increase in cash and cash equivalents	63	(36)
Cash and cash equivalents at the beginning of the year	29	65
Cash and cash equivalents at the end of the year	92	29

Notes to the Cash Flow Statement

- The above cash flow statement has been prepared under the "Indirect method" as set out in Ind AS-7 "Statement of Cash Flows".
- All figures in brackets are outflows.
- Summary of Cash and cash equivalents and Bank balance:

	As at March 31		
	2026	2025	2024
Cash and Cash Equivalents	92	29	65
Total	92	29	65

- Change in liability arising from financing activities:

	INR-Thousands
	Borrowings
	Long term
	[Note-8]
As at March 31, 2024	2,156
Cash flow	-
As at March 31, 2025	2,156
Cash flow	100
Opening interest added to borrowings	523
As at March 31, 2026	2,779

As per our report of even date

For Mukesh M. Shah & Co.,
Chartered Accountants
Firm Registration Number: 106625W

For and on behalf of the Board

sd/-
Harish B. Sadana
Director
[DIN : 00026483]

sd/-
Chandresh S. Shah
Partner
Membership Number: 042132
Ahmedabad, Dated: April 30, 2026

sd/-
Jyotindra B. Gor
Director
[DIN : 06439935]
Ahmedabad, Dated: April 30, 2026

Dialforhealth Unity Limited**Note: 1-Company overview:**

Dialforhealth Unity Limited ["the Company"] [CIN : U51390GJ2005PLC046314] was incorporated on June 23, 2005. The Company's registered office is situated at "Zydus Corporate Park", Sarkhej-Gandhinagar Highway, Near Vaishnodevi Circle, Ahmedabad - 382481. The Company has not carried out any business activity during the year. These financial statements were authorised for issue in accordance with a resolution passed by the Board of Directors at their meeting held on April 30, 2026.

Note: 2-Material Accounting Policies:

- A** The following note provides list of the material accounting policies adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented unless otherwise stated.
- 1 Basis of preparation:**
- A** The financial statements have been prepared in all material aspects in accordance with the Indian Accounting Standards [Ind AS] notified under section 133 of the Companies Act, 2013 read with [Indian Accounting Standards] Rules, 2015, as amended and other relevant provisions of the Companies Act, 2013.
- B** The financial statements have been prepared on historical cost basis, except for the following assets and liabilities which have been measured at fair value or revalued amount:
- i Certain financial assets and liabilities measured at fair value [refer accounting policy regarding financial instruments]
- 2 Use of key Estimates and Judgements:**
- The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the period. Application of accounting policies that require critical accounting estimates involving complex and subjective judgments are provided below. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the consolidated financial statements.
- 3 Revenue Recognition:**
- Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government and is shown net of returns, trade allowances, rebates, value added taxes and volume discounts.
- 4 Taxes on Income:**
- Tax expenses comprise of current and deferred tax.
- A Current Tax:**
- a Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.
- b Current tax items are recognised in co-relation to the underlying transaction either in Statement of Profit and Loss, OCI or directly in equity.
- B Deferred Tax:**
- Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.
- 5 Property, Plant and Equipment:**
- A** All other items of Property, Plant and Equipment are stated at historical cost of acquisition/ construction less accumulated depreciation and impairment loss. Historical cost [Net of Input tax credit received/ receivable] includes related expenditure and project expenses for the period up to completion of construction/ assets are ready for its intended use, if the recognition criteria are met and the present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset, if the recognition criteria for a provision are met. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.
- The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance costs are charged to the statement of profit and loss during the reporting period in which they are incurred, unless they meet the recognition criteria for capitalisation under Property, Plant and Equipment.
- B** Depreciation on tangible assets is provided on "straight line method" based on the useful lives as prescribed under Schedule II of the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used. However, management reviews the residual values, useful lives and methods of depreciation of Property, Plant and Equipment at each reporting period end and any revision to these is recognised prospectively in current and future periods.
- C** Depreciation on impaired assets is calculated on its reduced value, if any, on a systematic basis over its remaining useful life.
- D** Depreciation on additions/ disposals of the fixed assets during the year is provided on pro-rata basis according to the period during which assets are used.
- E** An item of Property, Plant and Equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset [calculated as the difference between the net disposal proceeds and the carrying amount of the asset] is included in the Statement of profit and loss when the asset is derecognised.
- 6 Borrowing Costs:**
- A** Borrowing costs consist of interest and other borrowing costs that are incurred in connection with the borrowing of funds.
- 7 Cash and Cash Equivalents:**
- Cash and Cash equivalents for the purpose of Cash Flow Statement comprise cash and cheques in hand, bank balances, demand deposits with banks where the original maturity is three months or less and other short term highly liquid investments.
- 8 Financial Instruments:**
- A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.
- A Financial Assets:**
- a Initial recognition and measurement:**
- All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction cost that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place [regular way trades] are recognised on the settlement date, i.e., the date that the Company settles to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

Note: 2-Material Accounting Policies (Continued)**b Subsequent measurement:**

For purposes of subsequent measurement, financial assets are classified in five categories:

i Debt instruments at amortised cost:

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- The asset is held with an objective of collecting contractual cash flows
- Contractual terms of the asset give rise on specified dates to cash flows that are "solely payments of principal and interest" [SPPI] on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate [EIR] method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of profit and loss.

ii Debt instruments at fair value through other comprehensive income [FVTOCI]:

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- The asset is held with objectives of both collecting contractual cash flows and selling the financial assets
- The asset's contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the Statement of Profit and Loss.

On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to Statement of Profit and Loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

iii Debt instruments and derivatives at fair value through profit or loss [FVTPL]:

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. Instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

B Financial Liabilities:**a Initial recognition and measurement:**

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

b Subsequent measurement:

Subsequently all financial liabilities are measured at amortised cost, using EIR method. Gains and losses are recognised in Statement of profit and loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of profit and loss.

c Derecognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of profit and loss.

9 Fair Value Measurement:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a In the principal market for the asset or liability, or
- b In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- a Level 1 — Quoted [unadjusted] market prices in active markets for identical assets or liabilities
- b Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- c Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation [based on the lowest level input that is significant to the fair value measurement as a whole] at the end of each reporting period.

10 Earnings per Share:

Basic earnings per share is calculated by dividing the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a right issue, shares split and reserve share splits [consolidation of shares] that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

Dialforhealth Unity Limited**Note: 2-Material Accounting Policies (Continued)****B Recent Accounting Pronouncements:**

The Ministry of Corporate Affairs [MCA] notifies new standards or amendments to existing standards under the Companies [Indian Accounting Standards] Rules from time to time. MCA has notified amendments to Ind AS 1 – Presentation of Financial Statements [classification of liabilities as Current or Non-current, including liabilities with covenants], Ind AS 12 – Income Taxes [International Tax Reform – Pillar Two Model Rules], Ind AS 21 – The Effects of Changes in Foreign Exchange Rates [Lack of Exchangeability] and Ind AS 7 – Statement of Cash Flows and Ind AS 107 – Financial Instruments: Disclosures [Supplier Finance Arrangements], effective from April 1, 2025. The Company has reviewed these amendments and based on its evaluation, has determined that they do not have any material impact on the Company's financial statements.

New standards or amendments not yet adopted:

Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants – Amendments to Ind AS 1. The amendments clarify that lender waivers obtained after the reporting date cannot be considered for the purpose of classifying liabilities as current or non current and require retrospective application in accordance with Ind AS 8. These amendments are effective for reporting periods beginning on or after April 1, 2026. The Company has no impact of these amendments in its classification criteria of current and non-current liabilities

Dialforhealth Unity Limited			
Notes to the Financial Statements			
		INR-Thousands	
		As at March 31	
		2026	2025
Note: 3-Property, Plant and Equipment:			
Furniture and Fixtures:			
Gross Block:			
As at March 31, 2024	99		99
Additions	-		-
Disposals	-		-
As at March 31, 2025	99		99
Additions	-		-
Disposals	-		-
As at March 31, 2026	99		99
Depreciation:			
As at March 31, 2024	99		99
Additions	-		-
Disposals	-		-
As at March 31, 2025	99		99
Charge for the year	-		-
Disposals	-		-
As at March 31, 2026	99		99
Net Block	-		-
Note: 4-Other Financial Assets:			
[Unsecured, Considered Good]			
Security Deposits	25		25
Total	25		25
Note: 5-Cash and Cash Equivalents:			
Balances with Banks		92	29
Total		92	29
Note: 6-Equity Share Capital:			
Authorised:			
7,50,000 [as at March 31, 2025: 7,50,000] Equity Shares of Rs.10/- each		7,500	7,500
		7,500	7,500
Issued, Subscribed and Paid-up:			
50,000 [as at March 31, 2025: 50,000] Equity Shares of Rs.10/- each, fully paid-up		500	500
Total		500	500
A There is no change in the number of equity shares as at the beginning and end of the year.			
Number of equity shares at the beginning and at the end of year		50,000	50,000
B The Company has only one class of equity shares having a par value of Rs. 10/- per share. Each holder of equity share is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the Annual General Meeting, except in the case of interim dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remaining after distribution of all preferential amounts.			
C Details of Share Holders holding more than 5% of Equity Shares of Rs. 10/- each, fully paid:			
Zydus Lifesciences Limited and its nominees:			
Number of Shares		27,500	27,500
% to total share holding		55%	55%
Dahyabhai N. Patel:			
Number of Shares		22,300	22,300
% to total share holding		45%	45%
D Details of Equity Shares held by promoters at the end of the year March 31, 2026 and 2025:			
Promoter's Name	No. of Shares	% of total shares	% change during the year
Zydus Lifesciences Limited	27,500	55%	-
Dahyabhai N. Patel	22,300	45%	-
Note: 7-Other Equity:			
Retained Earnings:			
Balance as per last Balance Sheet		(3,505)	(3,304)
Add: Loss for the year		(246)	(201)
Total		(3,751)	(3,505)

Dialforhealth Unity Limited						
Notes to the Financial Statements						
					INR-Thousands	
					As at March 31	
					2026	2025
Note: 8- Non Current-Borrowings:						
From Related Parties [Unsecured]					2,779	2,156
Total					2,779	2,156
[*] Borrowings from Related Parties: [Refer Note-18 for relationship]:					2,779	2,156
i Borrowings of INR 2,572 Thousand from Holding company will be repaid on or before March 31, 2030.The outstanding amount as at March 31, 2026 is INR 2,572 Thousand [as at March 31, 2025: 2,056 Thousand].						
ii Borrowings of INR 207 Thousand from one of the fellow subsidiary companies will be repaid within 5 years from the date of first disbursement.The outstanding amount as at March 31, 2026 is INR 207 Thousand [as at March 31, 2025: 100 Thousand].						
The interest rates on the above borrowings are Treasury Bill/ G Sec plus a margin.						
Note: 9- Other Financial Liabilities:						
Interest accrued but not due on borrowings					182	498
Total					182	498
Note: 10-Trade Payables:						
Dues to Micro and Small Enterprises [*]					6	12
Dues to Other than Micro and Small Enterprises					375	375
Total					381	387
[*]						
[*] Disclosure in respect of Micro and Small Enterprises:						
A Principal amount remaining unpaid to any supplier as at year end					6	12
B Interest due thereon						
C Amount of interest paid by the Company in terms of section 16 of the MSMED Act, along with the amount ok the payment made to the supplier beyond the appointed day during the year						
D Amount of interest due and payable for the year of delay in making payment [which have been paid but beyond the appointed day during the year] but without adding the interest specified under the MSMED Act						
E Amount of interest accrued and remaining unpaid at the end of the accounting year						
F Amount of further interest remaining due and payable in succeeding years						
The above information has been compiled in respect of parties to the extent to which they could be identified as Micro, Small and Medium Enterprises on the basis of information available with the Company.						
Trade Payables ageing						
Particulars	Not due	Outstanding from due date of payment				Total Payables
		Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	
As at March 31,2026						
Undisputed Micro and Small Enterprises [MSME]	6	-	-	-	-	6
Undisputed Others	-	-	-	-	375	375
Disputed MSME	-	-	-	-	-	-
Disputed Others	-	-	-	-	-	-
Total	6	-	-	-	375	381
As at March 31, 2025						
Undisputed Micro and Small Enterprises [MSME]	12	-	-	-	-	12
Undisputed Others	-	-	-	-	375	375
Disputed MSME	-	-	-	-	-	-
Disputed Others	-	-	-	-	-	-
Total	12	-	-	-	375	387
Relationship with struck off companies :						
Name of struck off company	Relationship with struck off company	Nature of Transactions	Transaction during year ended March 31		Balance outstanding as at March 31	
			2026	2025	2026	2025
Unity Chemists and Druggists Private Limited	Refer Note 18	Payables	-	-	375	375
Note: 11-Other Financial Liabilities:						
Payable to related parties [Refer Note No: 18]					6	-
Total					6	-
Note: 12-Other Current Liabilities:						
Payable to Statutory Authorities					20	18
Total					20	18

Dialforhealth Unity Limited			
Notes to the Financial Statements			
	INR-Thousands		
	Year ended March 31		
	2026	2025	
Note: 13-Finance Cost:			
Interest Expenses [*] [Refer Note-18]	230	176	
Total	230	176	
[*] The break up of interest expense into major heads is given below:			
On loans from related parties	230	176	
Note: 14-Other Expenses:			
Legal and professional expense	6	15	
Other Expenses	10	10	
Total	16	25	
[*] Legal and Professional Fees include:			
Payment to the Statutory Auditors [including GST]:			
i - As Auditor	6	6	
Note: 15-Tax Expenses:			
Considering principle of prudence, deferred tax assets are not recognised in absence of convincing evidence that sufficient future taxable income will be available against which such deferred tax assets can be realised.			
Note: 16-Calculation of Earnings per Equity Share [EPS]:			
The numerators and denominators used to calculate the basic and diluted EPS are as follows:			
a Loss attributable to Shareholders	INR-Thousands	(246)	(201)
b Basic and weighted average number of Equity shares outstanding during the year	Numbers	50,000	50,000
c Nominal value of equity share	INR	10	10
d Basic & Diluted EPS	INR	(4.92)	(4.02)
Note: 17-Segment Information:			
The Company has not carried out any commercial activity during the year, hence, segment reporting is not required.			
Note: 18-Related Party Transactions:			
A Name of the Related Party and Nature of the Related Party Relationship:			
a Holding Company:			
Zydus Lifesciences Limited [ZLL]			
b Fellow Subsidiary companies/ Firms:			
Zydus Healthcare Limited	Zydus Pharmaceuticals (USA) Inc. [ZPUI] [USA]		
German Remedies Pharmaceuticals Private Limited	Nesher Pharmaceuticals (USA) LLC [USA] [Merged with ZPUI w.e.f. October 25, 2024]		
Zydus Wellness Limited	ZyVet Animal Health Inc. [USA]		
Zydus Wellness Products Limited	Zydus Healthcare (USA) LLC [USA]		
Liva Nutritions Limited	Sentynt Therapeutics Inc. [USA]		
Liva Investment Limited [upto August 20, 2025]	Viona Pharmaceuticals Inc. [USA]		
Zydus Animal Health and Investments Limited [ZAHIL]	Zydus Therapeutics Inc. [USA]		
Dialforhealth Greencross Limited	Zynext Ventures USA LLC [USA]		
Violio Healthcare Limited	Zydus Healthcare S.A. (Pty) Ltd [South Africa]		
Zydus Pharmaceuticals Limited	Alidac Pharmaceuticals SA Pty. Ltd. [South Africa]		
Biochem Pharmaceutical Private Limited	Script Management Services (Pty) Ltd [South Africa]		
Zydus Strategic Investments Limited	Zydus Wellness [BD] Pvt Ltd [Bangladesh]		
Zydus VTEC Limited	Zydus Pharmaceuticals Mexico SA De C.V. [Mexico]		
LM Manufacturing India Private Limited	Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico]		
M/s. Recon Pharmaceuticals and Investments, a Partnership Firm	Zydus Worldwide DMCC [UAE]		
Zydus Medtech Private Limited [w.e.f. May 31, 2024]	Zydus Wellness International DMCC [UAE]		
Naturell (India) Private Limited [w.e.f. December 2, 2024, under liquidation]	Zydus Lifesciences Global FZE [UAE]		
Zydus International Private Limited [Ireland]	Zydus Pharmaceuticals (Canada) Inc. [Canada]		
Zydus Netherlands B.V. [the Netherlands]	Zydus Pharmaceuticals UK Limited [UK]		
Zydus Lanka (Private) Limited [Sri Lanka]	LM Manufacturing Limited [UK]		
Zydus Nikkho Farmaceutica Ltda. [Brazil]	Medsolutions (Europe) Limited [UK]		
Alidac Healthcare (Myanmar) Limited [Myanmar]	LiqMeds Worldwide Limited [UK]		
Zydus Healthcare Philippines Inc. [Philippines]	LiqMeds Limited [UK]		
Zynext Ventures PTE. LTD. [Singapore]	LiqMeds Lifecare Limited [UK] [LiqMed]		
Zydus France, SAS [France]	Naturell Inc. [USA] [w.e.f. December 2, 2024]		
Laboratorios Combix S.L. [Spain]	Amplitude Nord SAS [France] [w.e.f. July 29, 2025]		
Etna Biotech S.R.L. [Italy] [Under Liquidation]	Ortho Santé (Amplitude Ouest) [France] [w.e.f. July 29, 2025]		
Zylidac Bio LLC [USA] [w.e.f. July 11, 2025]	Amplitude Benelux [Belgium] [w.e.f. July 29, 2025]		
Zydus MedTech (France) SAS [France] [w.e.f. April 10, 2025]	Amplitude Suisse SA [Switzerland] [w.e.f. July 29, 2025]		
Amplitude Surgical SAS [France] [w.e.f. July 29, 2025]	Amplitude GmbH [Germany] [w.e.f. July 29, 2025]		
Amplitude Orthopedics Corporation [USA] [w.e.f. July 29, 2025]	Amplitude New Zealand Limited [New Zealand] [w.e.f. July 29, 2025]		
Amplitude Australia Pty Ltd [Australia] [w.e.f. July 29, 2025]	Auroralux [Luxemburg] [w.e.f. July 29, 2025 till December 31,2025]		
Amplitude South Africa Pty Ltd [South Africa] [w.e.f. July 29, 2025]	Ampliman 1 [France] [w.e.f. July 29, 2025 till January 16,2026]		
Amplitude Latin America SA [Brazil] [w.e.f. July 29, 2025]			

Dialforhealth Unity Limited			
Notes to the Financial Statements			
Note: 18-Related Party Transactions (Continued):			
Amplitude SAS [France] [w.e.f. July 29, 2025]	Ampliman 2 [France] [w.e.f. July 29, 2025 till January 9,2026]		
SCI Les Tilleuls [France] [w.e.f. July 29, 2025]	Mediconseil [w.e.f. December 19, 2025]		
SCI SOFAB FALLA [France] [w.e.f. July 29, 2025]	Alidac UK Limited [w.e.f. August 5, 2025]		
Amplitude Ile de France [France] [w.e.f. July 29, 2025]	Comfort Click Limited [UK] [w.e.f August 29,2025]		
Duotech Amplitude SAS [France] [w.e.f. July 29, 2025]	Comfort Click Limited [Ireland] [w.e.f August 29,2025]		
Amplitude Sud SAS [France] [w.e.f. July 29, 2025]	Comfort Click LLC [USA] [w.e.f August 29,2025]		
Comfort Click Softech Pvt. Ltd. [w.e.f August 29,2025]			
c Joint Venture Companies of Holding Company/Fellow Subsidiaries:			
Zydus Hospira Oncology Private Limited	Bayer Zydus Pharma Private Limited [Upto May 2, 2024]		
Zydus Takeda Healthcare Private Limited	Oncosol Limited [JV of LiqMed]		
Sterling Biotech Limited [w.e.f. August 29, 2024] [JV of ZAHIL]			
d Enterprises significantly influenced by Directors and their relatives of company and its Holding Company with whom transactions have taken place:			
Unity Chemist & Druggists Private Limited			
e Key Managerial Personnel:			
Mr. Harish Sadana	Chairman		
Mr. Jyotindra B. Gor	Director		
Mr. Dahyabhai Patel	Director		
Mr. Chimanlal P. Patel	Director		
B Transactions with Related Parties:			
The following transactions were carried out with the related parties in the ordinary course of business:			
a Details relating to parties referred to in Note 18-A [a,b & d]			
<u>Nature of Transactions</u>		INR-Thousands	
		Year ended March 31	
		2026	2025
Finance:			
Interest paid:			
Zydus Lifesciences Limited	223		176
Zydus Animal Health and Investments Limited	7		-
Reimbursement of Expense paid			
Dialforhealth Greencross Limited	6		
Inter Corporate Loans Received:			
Zydus Animal Health and Investments Limited	100		100
		As at March 31	
	2026	2025	
Outstanding - Payables:			
Zydus Lifesciences Limited	2,747		2,396
Zydus Animal Health and Investments Limited	214		100
Dialforhealth Greencross Limited	6		
Unity Chemist & Druggists Private Limited	375		375
b There are no transactions with parties referred to in Note 18-A [c & e]			
Note: 19-Financial Instruments:			
A Fair values hierarchy:			
Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three Levels of a fair value hierarchy. The three Levels are defined based on the observability of significant inputs to the measurement, as follows:			
Level 1: Quoted prices [unadjusted] in active markets for financial instruments.			
Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data rely as little as possible on entity specific estimates.			
Level 3: If one or more of the significant inputs is not based on observable market data.			
B Fair value of instruments measured at amortised cost:			
Financial Assets:			
The carrying amounts of other financial assets, cash and cash equivalents, are considered to be the approximately equal to the fair values.			
Financial Liabilities:			
Fair values of borrowings, other financial liabilities and trade payables are considered to be approximately equal to the carrying values.			

Dialforhealth Unity Limited					
Notes to the Financial Statements					
Note: 20-Financial Risk Management:					
A Financial instruments by category:					
	INR-Thousands				
	As at March 31, 2026				
	FVTPL	FVOCI	Amortised Cost	Total	
	Financial assets:				
	Security Deposits	-	25	25	
	Cash and Cash Equivalents	-	92	92	
	Total	-	117	117	
	Financial liabilities:				
	Borrowings	-	2,779	2,779	
	Trade payables	-	381	381	
	Other Non Current Financial Liabilities	-	182	182	
	Other Current Financial Liabilities	-	6	6	
	Total	-	3,348	3,348	
	As at March 31, 2025				
	FVTPL	FVOCI	Amortised Cost	Total	
Financial assets:					
Security Deposits	-	25	25		
Cash and Cash Equivalents	-	29	29		
Total	-	54	54		
Financial liabilities:					
Borrowings	-	2,156	2,156		
Trade payables	-	387	387		
Other Non Current Financial Liabilities	-	498	498		
Total	-	3,041	3,041		
B Risk Management:					
The Company's risk management is done in close co-ordination with the board of directors. The Company does not actively engage in the trading of financial assets for speculative purposes nor does it write options.					
Maturities of financial liabilities:					
The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.					
	INR-Thousands				
	< 1 year	1-2 year	2-3 year	> 3 years	Total
	As at March 31, 2026				
	Non-derivative Financial Liabilities:				
	Borrowings	-	-	2,779	2,779
	Trade payable	381	-	-	381
	Other Non Current Financial Liabilities	-	-	182	182
	Other Current Financial Liabilities	6	-	-	6
	Total	387	-	2,961	3,348
	As at March 31, 2025				
	Non-derivative Financial Liabilities:				
	Borrowings	-	-	2,156	2,156
	Trade payable	387	-	-	387
	Other Non Current Financial Liabilities	-	-	498	498
	Other Current Financial Liabilities	-	-	-	-
Total	387	-	2,654	3,041	

Dialforhealth Unity Limited						
Notes to the Financial Statements						
Note: 21-Analytical Ratios:						
No.	Ratio	Numerator	Denominator	FY 25-26	FY 24-25	% Change
1	Current Ratio[*]	Current Assets	Current Liabilities	0.23	0.07	215.68%
2	Debt-Equity Ratio	Total Debt	Shareholder's Equity	-0.85	-0.72	-19.14%
3	Debt Service Coverage Ratio[\$]	Earnings available for debt service	Finance Cost + Repayment of debt	-0.70	-1.39	49.91%
4	Return on Equity Ratio	Net Profits after taxes	Average Shareholder's Equity	-7.9%	-6.9%	-13.64%
5	Inventory turnover ratio	Net Sales	Average Inventory	N/A	N/A	N/A
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	N/A	N/A	N/A
7	Trade payables turnover ratio[^]	Net Purchases and Other Expenses	Average Trade Payables	0.04	0.07	-36.00%
8	Net capital turnover ratio	Net Sales	Average Working Capital	0.00	0.00	N/A
9	Net profit ratio	Net Profits after taxes	Net Sales	N/A	N/A	N/A
10	Return on Capital employed [\$]	Earnings before interest and taxes	Average Capital Employed	-4.6%	-3.3%	-37.26%
11	Return on investment	Income from investments during the year	Time weighted average of investments	N/A	N/A	N/A
[*] Mainly due to increase in cash and cash equivalents [\$] Due to increase in finance cost [^] Due to decrease in other expense						
Note: 22:						
The Company is not carrying commercial activity, however, the accounts of the Company are continued to be prepared on the assumption of Going Concern basis in view of: a Continuous support extended by the Holding Company and b Long term strategic involvement of the Holding company in the business affairs of the company.						
Note: 23:						
a The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities [Intermediaries] with the understanding that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company [Ultimate Beneficiaries] or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries. b The Company has not received any fund from any person(s) or entity(ies), including foreign entities [Funding Party] with the understanding [whether recorded in writing or otherwise] that the Company shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party [Ultimate Beneficiaries] or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries. c. The Company has used accounting software for maintaining its books of accounts for the year ended on March 31, 2026 which has a feature of recording audit trail [edit log] facility and the same has been operational throughout the year for all relevant transactions recorded in the software. Audit trail has been preserved by the Company as per the statutory requirements for record retention. d. The Company has not traded or invested in Crypto currency or Virtual currency during the financial year. e. No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transactions [Prohibition] Act, 1988 (45 of 1988) and the rules made thereunder f. The Company has not been declared as wilful defaulter by any bank or financial Institution or other lender. g. The Company does not have any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period. h. The Company has complied with the number of layers prescribed under clause [87] of section 2 of the Act read with Companies [Restriction on number of Layers] Rules, 2017 i. No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013. j. The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 [such as, search or survey or any other relevant provisions of the Income Tax Act, 1961].						
Note: 24:						
Figures of previous reporting year have been regrouped/ reclassified to conform to current year's classification.						
Signatures to Material Accounting Policies and Notes 3 to 24 to the Financial Statements						
As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants Firm Registration Number: 106625W			For and on behalf of the Board			
sd/- Chandresh S. Shah Partner Membership Number: 042132 Ahmedabad, Dated: April 30, 2026			sd/- Harish B. Sadana Director [DIN : 00026483]			
			sd/- Jyotindra B. Gor Director [DIN : 06439935] Ahmedabad, Dated: April 30, 2026			